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Chromosomal translocations involving the MALT1 gene are hall-
marks of mucosa-associated lymphoid tissue (MALT) lymphoma.
To date, targeting these translocations to mouse B cells has failed
to reproduce human disease. Here, we induced MALT1 expression
in mouse Sca1+Lin− hematopoietic stem/progenitor cells, which
showed NF-κB activation and early lymphoid priming, being selec-
tively skewed toward B-cell differentiation. These cells accumu-
lated in extranodal tissues and gave rise to clonal tumors
recapitulating the principal clinical, biological, and molecular ge-
netic features of MALT lymphoma. Deletion of p53 gene acceler-
ated tumor onset and induced transformation of MALT lymphoma
to activated B-cell diffuse large-cell lymphoma (ABC-DLBCL). Treat-
ment of MALT1-induced lymphomas with a specific inhibitor of
MALT1 proteolytic activity decreased cell viability, indicating that
endogenous Malt1 signaling was required for tumor cell survival.
Our study shows that human-like lymphomas can be modeled in
mice by targeting MALT1 expression to hematopoietic stem/pro-
genitor cells, demonstrating the oncogenic role of MALT1 in lym-
phomagenesis. Furthermore, this work establishes a molecular link
between MALT lymphoma and ABC-DLBCL, and provides mouse
models to test MALT1 inhibitors. Finally, our results suggest that
hematopoietic stem/progenitor cells may be involved in the path-
ogenesis of human mature B-cell lymphomas.
molecular-directed therapy | transgenic mice | cancer stem cells |
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Mucosa-associated lymphoid tissue (MALT) lymphoma isa distinct clinicopathological entity that accounts for 8% of
all non-Hodgkin lymphomas (1, 2). MALT lymphomas can be
distinguished from other lymphomas because they occur in vari-
ous extranodal locations, primarily in the stomach, where they are
preceded by Helicobacter pylori infection, and also in the ocular
adnexa, lung, salivary glands, intestinal tract, skin, thyroid, and
genitourinary tract, and are associated with chronic microbial
infections or autoimmune disorders. MALT lymphomas show
a typical histopathological picture composed of a heterogeneous
neoplastic B-cell population that arises from the marginal zone of
reactive B-cell follicles, extends to the interfollicular region, and
infiltrates the epithelium, forming the characteristic lymphoepi-
thelial lesions. Additionally, these lymphomas frequently show a
prominent plasmacytic differentiation (1–3).
Genetically, MALT lymphomas are mainly associated with
two chromosomal translocations involving theMALT1 gene. The
t(11;18)(q21;q21), which generates an API2-MALT1 fusion
transcript, occurs in up to 30% of the cases, whereas the t(14;18)
(q32;q21) results in the immunoglobulin H (IGH)-MALT1
translocation and is detected in 15–20% of the cases (4–6). A
third translocation, the t(1;14)(p22;q32), forms a B-cell BCL10-
IGH fusion and is present in ∼1% of MALT lymphomas. All of
these translocations lead to the activation of NF-κB, which
regulates target genes involved in immune responses to foreign
antigens (7). In B lymphocytes, MALT1 is part of the CARD11/
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BCL10/MALT1 (CBM) complex, a mediator of the stimulation
of the B-cell antigen receptor (BCR). MALT1 mediates the
activation of the IκB kinase (IKK) complex, leading to the re-
lease and nuclear translocation of NF-κB. Remarkably, the
caspase-like domain of MALT1 shows proteolytic activity and
can cleave BCL10 and several NF-κB inhibitors, resulting in NF-
κB activation (7–9). In MALT lymphomas, it is assumed that
underlying chronic infection/inflammation causes persistent
BCR-mediated NF-κB activation that promotes B-lymphocyte
expansion and accumulation in extranodal tissues, ultimately
resulting in clonal lymphoma development (1, 3).
Emerging data also implicate the CBM complex in the patho-
genesis of diffuse large cell lymphoma of activated B cells (ABC-
DLBCL), a distinct lymphoma subtype that can be distinguished
from the germinal center B-cell-like (GCB)-DLBCL (10, 11).
Like in MALT lymphomas, a hallmark of ABC-DLBCL is the
constitutive signaling of the NF-κB pathway, which is caused by
mutations in various genes regulating NF-κB, including activating
mutations of CARD11, CD79A, CD79B, and MyD88, and inacti-
vating mutations of TNFAIP3 (11). Notably, mutations inMyD88
and TNFAIP3 genes have been also found in MALT lymphomas,
suggesting a molecular link between ABC-DLBCL and MALT
lymphoma (11). However, this relationship has not been proved
experimentally.
Despite these evidences, a causative role for MALT1 in the
development of MALT lymphoma has not been demonstrated.
Indeed, the expression of API2-MALT1 or BCL10 in B lympho-
cytes did not induce lymphoma in mice (12, 13), suggesting that
NF-κB activation in B cells may not be sufficient to promote ma-
lignant transformation. The lack of genetically engineered human-
like MALT lymphoma models has hampered a better under-
standing of the disease pathogenesis and the development of
MALT1-targeted therapies, the relevance of which to the treat-
ment of ABC-DLBCL, an aggressive lymphoma that responds
poorly to current immunochemotherapies, has already been
highlighted using in vitro cell models (14, 15).
In this work, we show that human MALT lymphoma patho-
genesis can be modeled in mice by targeting MALT1 expression
to hematopoietic stem/progenitor cells, demonstrating the on-
cogenic role of MALT1 in lymphomagenesis. Furthermore, our
study establishes a molecular link between MALT lymphoma
and ABC-DLBCL and provides mouse models to test therapies
targeting MALT1.
Results
MALT1 Shows Oncogenic Properties in Primitive Hematopoietic Cells.
Given that the expression of the MALT lymphoma-related genes
in mouse B lymphocytes does not induce lymphoma develop-
ment, we first explored whether MALT1, BCL10, or API2-
MALT1 could be tumorigenic in more primitive hematopoietic
cells. Human full-length MALT1 and BCL10 genes and the
API2-MALT1 fusion gene were stably transfected into murine
IL3-dependent hematopoietic BaF3 cells activated with anti-
mouse IgM, anti-mouse CD40 antibody, and recombinant mIL4.
Isolated single-cell clones expressing MALT1, BCL10, or API2-
MALT1 genes exhibited higher NF-κB activation with respect to
control cells, but only MALT1-expressing cells grew indepen-
dently of IL3 (SI Appendix, Fig. S1 A and B). Accordingly, i.v.
injection of 1 × 106 cells expressing MALT1, BCL10, and API2-
MALT1 into BALB/c nude mice revealed that only MALT1-
expressing cells generated tumors that rapidly killed the mice (SI
Appendix, Fig. S1C). However, the MALT1-driven leukemias
were composed of highly proliferating large lymphoid cells with
a CD19−B220weakCD5−IgM− phenotype that did not reproduce
the clinicopathological features of MALT lymphoma (SI Ap-
pendix, Fig. S1 D and E).
In Vivo Model of Ectopic Expression of Human MALT1 Protein in
Hematopoietic Stem/Progenitor Cells. Having demonstrated that
MALT1 can transform primitive hematopoietic cells, we gener-
ated transgenic mice in which the mouse stem cell antigen 1
(Sca1, Ly-6E.1) gene promoter was used to drive the expression
of the humanMALT1 gene in the hematopoietic stem/progenitor
cell compartment of C57BL/6 × CBA mice (Fig. S2A) (16).
Southern blot analysis of the three founders obtained showed
transgene copy numbers ranging from ∼2 to 4 (SI Appendix, Fig.
S2B). Measurement of MALT1 mRNA expression levels by
RT-PCR showed expression of the exogenous human MALT1
transgene in Sca1+Lin− hematopoietic/stem cells purified from
the bone marrow (BM) of Sca1-MALT1 mice, but not in wild-
type (WT) littermates (Fig. S2C). In addition, Sca1-driven hu-
man MALT1 expression was detected in Sca1+Lin− cells but not
in other lymphoid cell subpopulations, as determined by quan-
titative real-time PCR analysis performed in cells isolated from
BM, spleen and lymph nodes (SI Appendix, Fig. S2D). Likewise,
immunofluorescence and Western blot studies detected MALT1
protein in transgenic BM Sca1+Lin− cells but not in splenic
CD19+IgM+ mature B-lymphocytes, B220+CD21highCD23−
marginal zone B cells or thymic T cells (Fig. 1C and SI Appendix,
Fig. S2 F and G). These results document that human MALT1
expression is restricted to Sca1+Lin− cells of Sca1-MALT1 mice,
validating the model for the functional analysis of MALT1 ex-
pression in hematopoietic stem/progenitor cells in vivo.
Expression of MALT1 in Sca1+ Cells Induces NF-κB Signaling, Promotes
Hematopoietic Stem/Progenitor Cell Expansion, and Enhances B-Cell
Lymphopoiesis in Young Mice. Flow cytometric analysis of the
different hematopoietic cell compartments in 2-mo-old Sca1-
MALT1 mice did not detect major abnormalities in myeloid or
T-cell subpopulations (as determined by Gr1, Mac1, CD4, or
CD8 staining) in BM, peripheral blood (PB), spleen, and thymus
(SI Appendix, Fig. S2H). However, an expansion of the hema-
topoietic stem/progenitor Sca1+Kit+Lin− cells was detected in
the BM of transgenic mice in comparison with WT littermates
(1.24% vs. 0.44%) (Fig. S2I). This expansion was accompanied
by increased numbers of pro-B and pre-B lymphoid cells in BM
(Fig. S2I) and with moderate accumulation of mature B cells in
PB and spleen but not in lymph nodes (Fig. S2I). To investigate
the molecular mechanisms underlying this enhanced B-cell
lymphopoiesis, the transcriptional profiles of BM-sorted Sca1+-
Lin− cells from transgenic and WT mice were compared using
gene-expression microarrays (SI Appendix, Fig. S2J). Linear
Models of Microarray Data Analysis (LIMMA) identified 110
genes differentially expressed between transgenic and WT cells
[false discovery rate (FDR) < 0.19; P < 0.0006), defining the
Sca1+Lin− MALT1 signature. This included underexpression of
genes encoding essential regulators of early B-cell development
[Sox4, E2A (Tcef2a), Vpreb1, Vpreb2, and Rag1/Rag2], and up-
regulation of differentiated B-cell markers (Prdm1, Xbp1, and Ig
genes) (Fig. S2K and SI Appendix, Table S1). Gene Set Enrich-
ment Analysis (GSEA) determined that the Sca1+Lin− MALT1
dataset was significantly enriched in NF-κB target genes (FDR =
0.009; http://www.bu.edu/nf-kb/gene-resources/target-genes), which
is consistent with the activation of NF-κB pathway in Sca1+Kit+
Lin− cells (Fig. S2L). Additionally, Ingenuity Pathway Analysis
(IPA) (Ingenuity Systems) identified that the Sca1+Lin−MALT1
dataset was enriched in inflammatory response genes [FDR
(Benjamini–Hochberg) < 1 × 10−10] (SI Appendix, Fig. S2M).
These results indicate that MALT1-driven NF-κB activation
induced the expansion of mouse BM hematopoietic stem/pro-
genitor cells, which showed an abnormal early expression of
B-cell markers and were selectively directed toward B-cell dif-
ferentiation, promoting the accumulation of mature B lympho-
cytes in extranodal tissues.
Sca1-MALT1 Mice Develop Human-Like MALT Lymphomas. Adult
Sca1-MALT1 transgenic mice developed clinical signs of disease,
having a shorter lifespan in comparison with their WT littermates
(Fig. 1A and SI Appendix, Table S2A). Systematic necropsies in
transgenic mice (n = 60) showed consistent macroscopic tumors
(Fig. 1B) and the presence of normocytic anemia (SI Appendix,
Fig. S2N). Tumors involved different extranodal sites such as the
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small intestine, salivary glands, kidneys, lungs, liver, stomach,
ocular adnexa, and spleen but did not affect the lymph nodes (Fig.
1C). More than one site of involvement was observed in 17 of 26
(65%) Sca1-MALT1 mice with macroscopic abnormalities (SI
Appendix, Table S2B). Histological examination of the tumors
revealed an extranodal cell infiltration comprising a morphologi-
cally heterogeneous lymphoid population, predominantly com-
posed of marginal zone (centrocyte-like) cells mixed up with small
lymphocytes, scattered large blasts, and plasma cells (Fig. 2 A and
B). The neoplastic lymphoid infiltrate was located in the marginal
zone of the B follicles, surrounding reactive germinal centers and
extending into the interfollicular region. In epithelial tissues, the
cells infiltrated the epithelium and formed lymphoepithelial
lesions (Fig. 2 A and B and SI Appendix, Fig. S3 A–E). Prominent
plasma cells were observed, particularly surrounding blood ves-
sels, showing pleomorphic features with occasional binuclei,
which suggests the neoplastic nature of at least a proportion of
these cells (Fig. 2C). Immunohistochemistry (IHC) analysis
showed that the lymphoid-infiltrating tumor cells expressed the B-
cell-specific markers CD20 and Pax5, with moderate to strong
IgM expression and weak IgD expression, whereas CD3 high-
lighted a few scattered T cells within the tumor (Fig. 2D and SI
Appendix, Fig. S3F). Most tumors were oligoclonal or clonal,
according to PCR and Southern blot analyses of V(D)J rear-
rangements. PCR amplification and sequencing of Ig-rearranged
genes, however, did not show somatic hypermutation in Sca1-
MALT1 mouse lymphomas (SI Appendix, Fig. S3G and H). As in
humans, mouse Sca1-MALT1 lymphomas frequently spread to
the spleen, and a spontaneous transformation to human-like
ABC-DLBCLs with a CD20+, Foxp1+, CD10−, Gcet1−, Mum1/
Irf4−, Bcl6− phenotype was observed in 4 of 26 (15%) mice (17,
18) (SI Appendix, Fig. S3I). Taken together, Sca1-MALT1 mice
developed mature B-cell lymphomas that involved extranodal
sites and displayed clinical, histological, immunophenotypic, and
genetic features resembling human MALT lymphoma.
Sca1-MALT1 Murine Lymphomas Share Abnormal Transcriptional and
Genomic Profiles with Human MALT Lymphomas.The transcriptional
signature of human MALT lymphoma has been incompletely
reported. Therefore, to compare the molecular profiles of mouse
Sca1-MALT1 lymphomas and human MALT lymphomas, gene-
expression microarrays were applied to diagnostic biopsies from
patients with MALT lymphoma and with other common B-cell
lymphoma subtypes (SI Appendix, Tables S2 C and D and Fig.
S4A). Bioinformatic analysis of microarray data using the Pre-
diction Analysis for Microarrays (PAM) software identified 132
genes that distinguished MALT lymphoma from other B-cell
lymphomas, thereby defining the human MALT lymphoma
transcriptional signature (SI Appendix, Table S3A and Fig. S4B).
A representative selection of deregulated genes (FCRL4-Irta1,
LTF, MEIS1, PBX1, ETV6, FZD7, and FOXO3) and proteins
[LTF and EGF receptor (EGFR)], selected using biological and
functional criteria because of their special interest for lym-
phoma, was studied by quantitative real-time PCR and IHC
analyses in normal tissue samples and lymphoma cells, validating
the microarray data (SI Appendix, Fig. S4 C and D). LIMMA
comparison of the gene-expression profiles between splenic
Sca1-MALT1 lymphomas and WT mouse spleens defined the
Sca1-MALT1 lymphoma transcriptional signature, composed of
246 differentially expressed genes (FDR < 0.058, P < 0.00063)
(Fig. 2E and SI Appendix, Table S3B). Bioinformatic studies
using GSEA revealed that the Sca1+Lin−MALT1 signature (see
Fig. S2K) was strongly conserved in the Sca1-MALT1 murine
lymphomas (FDR < 0.0001) (Fig. 2F). In addition, the tran-
scriptional profiles of both the Sca1-MALT1 lymphomas and
human MALT lymphomas were significantly enriched in NF-κB
target genes (GSEA, FDR < 0.0001) (Fig. 2G and SI Appendix,
Fig. S4E) and inflammatory response genes (Ingenuity function
enrichment analysis, FDR (Benjamini–Hochberg) <5%; P < 1 ×
10−10) (SI Appendix, Fig. S4 F and G). Moreover, the Sca1+Lin−
MALT1 signature was over-represented in human MALT lym-
phomas, but not in the other B-cell lymphoma subgroups (Fig.
2H). To gain further insight, we focused on the genes that were
over-expressed in the Sca1+Lin− MALT1 signature, such as
Prdm1, Xbp1 and Ig genes, which are involved in plasmacytic
differentiation. This process is defined at the molecular level by
an XBP1-target gene signature (19), which was significantly
enriched in the transcriptional profiles of Sca1+Lin− BM-sorted
cells (FDR < 0.001), Sca1-MALT1 mouse lymphomas (FDR <
0.001), and human MALT lymphomas (FDR < 0.05), but not in
the other B-cell lymphoma subgroups (FDR > 0.1) (SI Appendix,
Fig. S4H). In addition, the human MALT lymphoma transcrip-
tional signature was significantly enriched in the Sca1-MALT1
mouse lymphomas (FDR < 0.0001) (Fig. 2I). Finally, high-res-
olution microarray-based comparative genomic hybridization
(aCGH) analysis revealed that all nine Sca1-MALT1 mouse
lymphomas analyzed displayed genomic changes, including gains
of chromosome 14D3-qE3 (n = 8) and 17A1-E5 (n = 2), and loss
of chromosome 12A1-F2 (n = 2) (SI Appendix, Fig. S4 I and J).
These abnormalities are syntenic with the gains of chromosome
3p24 and 18p11 and with the loss of chromosome 7q21-q31, which
are common in human marginal-zone B-cell lymphomas (1).
These results indicate that human and mouse lymphomas display
similar genomic profiles and common molecular signatures,
sharing MALT1-mediated NF-κB activation, proinflammatory
signaling and XBP1-induced plasmacytic differentiation.
Deletion of p53 Accelerates Tumor Onset and Induces ABC-DLBCL in
Sca1-MALT1 Mice. Previous studies have shown that P53 in-
activation is associated with the transformation of MALT lym-
phoma to DLBCL (20). Based on these data, Sca1-MALT1 and
p53−/− mice were crossed to generate Sca1-MALT1,p53−/− mice
(21). Loss of p53 decreased the overall survival of Sca1-MALT1
mice (P < 0.0001, Log-rank (Mantel-Cox) test), which was sim-
ilar to that of p53−/− animals (P = 0.53) (Fig. 3A). However,
while p53−/− mice were killed by thymic T-cell lymphomas (21),
Sca1-MALT1,p53−/− mice developed aggressive lymphomas
characterized by a diffuse infiltrate of large B-lymphocytes with
nuclei with dispersed chromatin, deeply basophilic cytoplasm
and multiple mitotic figures, resembling human DLBCL (Fig. 3
B and C and SI Appendix, Fig. S5A). IHC studies revealed
moderate expression of CD20 and strong expression of Foxp1,
with negative expression for Bcl6, Gcet1, Mum1 (Irf4) and
A B
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Fig. 1. Sca1-MALT1 mice develop extranodal human-like MALT lymphomas.
(A) Kaplan–Meier overall survival plots of Sca1-MALT1 mice and WT litter-
mates. Differential survival was analyzed using the log-rank (Mantel–Cox)
test: line 86A vs. WT, P = 0.0007; line 86B vs. WT, P = 0.0026; and line 86C vs.
WT, P = 0.0173). (B) Macroscopic aspect of the tumors in small intestine,
spleen, and kidney of Sca1-MALT1 mice. (C) Tumor location of MALT lym-
phomas in 26 Sca1-MALT1 mice; note that 65% of mice developed tumors at
more than one site.
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CD10, and with few scattered CD3+ T cells, allowing their
classification as human-like ABC-DLBCL (17) (Fig. 3C). Nota-
bly, over-expression of FOXP1 is a common feature of aggressive
human ABC-DLBCL (22). PCR and Southern blot analyses of
the Sca1-MALT1,p53−/− lymphomas revealed their oligoclonal
and clonal nature in most cases (SI Appendix, Fig. S3 G and H).
Gene expression profiling analysis identified 34 genes differen-
tially expressed between B cells isolated from splenic Sca1-
MALT1,p53−/− lymphomas and from WT spleens (LIMMA;
FDR < 0.3; P < 0.0004) (Fig. 3D and SI Appendix, Table S3C).
GSEA using a gene-expression-based predictor to classify human
DLBCL (10) revealed that the ABC-DLBCL transcriptional
signature was highly enriched in the transcriptional profile of
Sca1-MALT1,p53−/− lymphomas when using the entire classifier
(FDR < 0.047) and specially when selecting the up-regulated
genes (FDR < 0.007) (Fig. 3E). Additionally, GSEA showed
a significant enrichment in NF-κB target genes in the Sca1-
MALT1,p53−/− lymphomas (FDR < 0.0001), which is one of the
main features of human ABC-DLBCL (7, 10, 11, 18) (Fig. 3F).
Finally, aCGH studies of clonal lymphomas developed in Sca1-
MALT1,p53−/− mice identified a complex pattern of DNA copy
number changes that were syntenic with the gain/amplification of
human chromosomes 18q21 (including the BCL2 gene locus)
and 3q25-q26.2, both of which are frequently observed in ABC-
DLBCL but not in GBC-DLBCL (23) (SI Appendix, Fig. S5 B
and C). These results demonstrate that p53 loss is associated with
the transformation of MALT lymphoma to human-like ABC-
DLBCL in Sca1-MALT1 mice, further corroborating the paral-
lelism between mouse and human disease.
Sca1-MALT1 and Sca1-MALT1,p53−/− Mice Are Useful Models to Test
MALT1 Inhibitors. Previous publications have reported that the
MALT1 caspase-like domain shows proteolytic activity that
can be inhibited by the peptidic inhibitor, z-VRPR-fmk (8, 9).
Measurement of Malt1 mRNA with murine-specific primers did
not identify higher Malt1 mRNA expression in Sca1-MALT1
lymphomas than in WT splenocytes (SI Appendix, Fig. S5D).
However, endogenous Malt1 showed proteolytic activity in the
murine lymphomas and cleaved Bcl10 (SI Appendix, Fig. S5E).
To evaluate whether our models may be suitable tools for testing
MALT1 inhibitors (14, 15), B220+ lymphoma B cells isolated
from transgenic mice were treated with the specific MALT1 in-
hibitor z-VRPR-fmk and with the NF-κB inhibitor Bay11-7082
(9). Both, Sca1-MALT1 and Sca1-MALT1,p53−/− lymphoma
cells showed a statistically significant increase in the apoptotic
rates upon incubation with z-VRPR-fmk (P < 0.05) (Fig. 3G) or
with Bay11-7082 (P < 0.05) (Fig. 3H and SI Appendix, Fig. S5F).
These data indicate that constitutive Malt1-induced NF-κB sig-
naling is required for lymphoma cell survival, suggesting that
these mice can be useful for testing MALT1 inhibitors.
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Fig. 2. Characterization of human-like MALT lymphomas arising in Sca1-MALT1 mice. (A) Representative hematoxylin–eosin (HE) staining analysis of the
mouse lymphomas. A typical lymphoid cell population is present in the small intestine of Sca1-MALT1 mice, infiltrating the lamina propria and the epithelium
in small groups, giving rise to lymphoepithelial lesions. (B) Lymphoid tumor cells also infiltrate other tissues. (C) Lymphomas developed in the kidneys showed
prominent plasma cells surrounding blood vessels, which were pleomorphic and showed occasional binuclei (marked with arrows). (D) IHC analysis of Pax5
expression in Sca1-MALT1 lymphomas. (E) Gene-expression microarray analysis defined the Sca1-MALT1 lymphoma transcriptional signature. Five Sca1-MALT1
splenic lymphomas and four WT spleen were studied. (F–I) Bioinformatic studies of Sca1-MALT1 murine lymphoma transcriptional signature using GSEA.
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Bone Marrow CD34+ Cells Isolated from Patients with MALT Lymphoma
Show an Aberrant Transcriptional Profile. To investigate whether
hematopoietic/stem cells could be involved in the pathogenesis
of MALT lymphoma, bone marrow CD34+ cells (with purity of
>95%) were isolated from six patients with MALT lymphoma
and of five healthy donors (SI Appendix, Table S4A). Using FISH
or semiquantitative RT-PCR, the t(11;18)(q21;q21) was detected
in the mature B-cell lymphoma cells of two patients but not in
the CD34+ cells (SI Appendix, Fig. S6 A and B). Gene-expres-
sion-profiling analysis of CD34+ cells isolated from MALT
lymphoma patients vs. healthy individuals identified 743 gene
probes differentially expressed (LIMMA; FDR < 0.017; P <
0.001) (SI Appendix, Fig. S6C). The human CD34+ MALT
lymphoma transcriptional signature revealed among the top bi-
ological functions “inflammatory response” and “antigen pre-
sentation” (SI Appendix, Fig. S6D). In addition, overexpression
of 23 gene probes that corresponded to Ig genes was detected in
MALT lymphoma CD34+ cells (SI Appendix, Table S4B). GSEA
identified that the human CD34+ MALT lymphoma dataset was
positively enriched in NF-κB target genes (FDR < 0.0001) (SI
Appendix, Fig. S6E). Moreover, the human CD34+ MALT
lymphoma transcriptional signature was significantly enriched in
the previously defined human MALT lymphoma dataset (FDR <
0.012) (SI Appendix, Fig. S6F) but not in the datasets from
patients with DLBCL (FDR = 0.059), follicular lymphoma
(FDR = 0.113), or splenic marginal-zone lymphoma (FDR =
0.357) (SI Appendix, Fig. S6 G–I). Finally, the molecular sig-
natures of both Sca1+Lin− cells and mature B-lymphoma cells
isolated from the Sca1-MALT1 mice were enriched in the human
CD34+ MALT lymphoma dataset (FDR < 0.0001 and FDR =
0.005, respectively) (SI Appendix, Fig. S6 J and K). These results
show that NF-κB and inflammatory signaling are present in human
MALT lymphoma CD34+ cells, along with the overexpression
of a set of Ig genes, which is compatible with early lymphoid
priming. Because these Ig genes are not normally expressed in
CD34+ cells but rather in committed B lymphocytes, our findings
suggest that the hematopoietic stem/progenitor cells may be in-
volved in the pathogenesis of human lymphoma.
Discussion
Understanding the biology underlying MALT lymphoma has
been hampered by the lack of genetically modified mouse models
that develop human-like tumors (1–3, 7). Here, we show that the
expression of human MALT1 in Sca1+Lin− hematopoietic stem/
progenitor cells induced an abnormal NF-κB signaling that
promoted expansion and early priming of these cells toward B-
cell differentiation, eventually resulting in the accumulation of
mature B lymphocytes in extranodal tissues and in progressive
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Fig. 3. Sca1-MALT1-p53−/− mice develop human-like ABC-DLBCL. (A) Kaplan–Meier survival plots of Sca1-MALT1, p53−/−, p53−/−, and control WT mice. (B)
Macroscopic aspect of the intestine and spleen in Sca1-Malt1,p53−/− mice vs. WT and p53−/− age-matched mice. (C) Representative hematoxylin–eosin (HE)
staining and IHC analysis for CD20, Foxp1, Mum1, Gcet1, CD10, and Bcl6 in Sca1-Malt1,p53−/−mice. Appropriate positive and negative control tissues for each
antibody were used (see Materials and Methods). (D) Heat-map image showing the Sca1-MALT1,p53−/− lymphoma transcriptional signature. B220+ cells
isolated from three Sca1-MALT1,p53−/− lymphomas and three WT spleens were studied. (E) GSEA showed a significant positive enrichment of the human ABC-
DLBCL transcriptional signature in Sca1-MALT1,p53−/− lymphomas. (F) Sca1-MALT1,p53−/− lymphomas were significantly enriched in NF-κB target genes. (G
and H) B220+ splenic B lymphoma cells isolated from three Sca1-MALT1 and three Sca1-MALT1,p53−/−mice were incubated with (+) or without (−) z-VRPR-fmk
(75 μM) (G) or Bay11-7082 (5 μM) (H) for 48 h. Induction of apoptosis was assessed by flow cytometry using annexin V/PI staining. Data represent the means ±
SD percentages of apoptotic cells from three independent experiments.
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lymphoma development. These tumors accurately reflected most
clinical, histopathological, genetic, and molecular features of
human MALT lymphomas (1–3). Further paralleling the natural
history of human disease, spontaneous transformation of mouse
MALT lymphoma to ABC-DLBCL was observed in a fraction of
Sca1-MALT1 mice, which was accelerated after the constitutive
deletion of the p53 gene (20). Therefore, human lymphoma
pathogenesis can be modeled in mice by targeting MALT1 ex-
pression to the hematopoietic stem/progenitor cells. Our results
also show that constitutive Malt1 signaling is required for the
survival of murine lymphoma cells, indicating that our transgenic
models may be suitable tools for developing and testing MALT1
inhibitors (24).
Additionally, our data suggest that hematopoietic/stem pro-
genitor cells may be involved in the development of mature B-
cell lymphomas. In support of this hypothesis, one recent report
demonstrated that patients can harbor inactivating mutations of
TET2 gene in hematopoietic stem cells that give rise to B-cell
lymphomas (25). Similarly, in B-cell chronic lymphocytic leuke-
mia (CLL), the propensity to generate clonal B cells had been
already acquired at the hematopoietic stem cell stage (26). Thus,
CLL-derived hematopoietic stem cells showed an abnormal ex-
pression of lymphoid-related genes, presumably reflecting their
cell-intrinsic priming into the lymphoid lineage (26). Although
our results indicate that hematopoietic stem/progenitor cells may
play a role in human mature B-cell lymphoma development, it
cannot be excluded, however, that the abnormal gene-expression
profile of human MALT lymphoma CD34+ cells could be con-
sequence of having cancer.
In summary, our study shows that human MALT lymphoma
pathogenesis can be modeled in mice by targeting MALT1 ex-
pression to hematopoietic stem/progenitor cells, demonstrating
the oncogenic role of MALT1 in lymphomagenesis. Further-
more, our findings establish a molecular link between MALT
lymphoma and ABC-DLBCL and provide mouse models to test
therapies targeting MALT1 proteolytic activity.
Materials and Methods
Generation of Transgenic Mice. The Sca1-MALT1 vector was generated by
inserting the human MALT1 cDNA into the ClaI site of the pLy6 vector. The
transgene fragment was excised from its vector by restriction digestion with
NotI, purified, and injected (2 ng/mL) into CBA × C57BL/6J fertilized eggs (16).
Heterozygous p53+/− mice (21) were bred to Sca1-MALT1 mice to generate
null p53−/− mice hemizygous for Sca1-MALT1. The study was performed in
accordance with Consejo Superior de Investigaciones Científicas, University of
Salamanca and University of Navarra Institutional Animal Care and Use
Committees and the Spanish National Institute of Health guidelines.
Patient Samples. Biopsies from patients with MALT lymphoma (n = 75), DLBCL
(n = 26), follicular lymphoma (n = 15), and splenic marginal B-cell lymphoma
(n = 12) were included in the study. For BM CD34+ cell isolation, Spanish
patients newly diagnosed with MALT lymphoma and healthy donors were
included. Informed consent was obtained from the patients in accordance
with the Declaration of Helsinki. The study was approved by Consejo Su-
perior de Investigaciones Científicas, University of Salamanca and University
of Navarra Institutional Research Ethics Committees.
Microarray Data. Affymetrix microarray data files are available at GEO (ac-
cession numbers GSE25636, GSE25637, GSE25638, GSE25639, and GSE34015).
Additional materials and methods are presented in SI Appendix.
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